Ataxia Market, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational T

Ataxia Market, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational Therapy)), by Disease Type (Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxias, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be classified into three types on the basis of cause: acquired ataxia, genetic ataxia, and idiopathic ataxia. Acquired ataxia is caused by external factors such as vitamin deficiencies, head trauma, microbial infection, brain tumor, and exposure to drugs or alcohol. Genetic ataxia is caused when a damaged gene which leads to ataxia is passed from one generation to the other. Idiopathic ataxia is a condition wherein the cause is unknown. Few of the symptoms associated with ataxia include decreasing coordination, trouble in walking, impaired balance with frequent falls, loss of fine motor skills, muscle tremors, slurred speech, vision problems, and others. Ataxia can develop at any age and is progressive in nature i.e. it worsens with time.
Market Dynamics
The increasing incidence of ataxia, rising research and development activities for the development of novel therapeutics for the treatment of ataxia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global ataxia market over the forecast period.
For instance, according to an article published by the Clinical and Translational Neuroscience journal, in August 2018, it is estimated that the global occurrence rate of ataxia is 26/100,000 in children wherein the occurrence rate for dominant hereditary cerebellar ataxia is 2.7/100,000 and the occurrence rate for recessive hereditary cerebellar ataxia 3.3/100,000, as of 2018.
Key features of the study:
This report provides in-depth analysis of the global ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ataxia market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ataxia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ataxia market
Detailed Segmentation:
Global Ataxia Market, By Treatment Type:
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
Global Ataxia Market, By Disease Type:
Friedreich's Ataxia
Ataxia-telangiectasia
Spinocerebellar Ataxias
Episodic Ataxia
Others (Multiple System Atrophy (MSA))
Global Ataxia Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Ataxia Market, By Region:
North America
By Treatment Type
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
By Disease Type
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Treatment Type
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
By Disease Type
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
By Disease Type
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
By Disease Type
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
By Disease Type
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Pharmacotherapy
Levodopa
Pramipexole
Desvenlafaxine
Venlafaxine
Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
Physical Therapy
Speech Therapy
Others (Adaptive Devices and Occupational Therapy)
By Disease Type
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
CRISPR Therapeutics
Acorda Therapeutics
Capsida Biotherapeutics Inc.
Larimar Therapeutics, Inc.
Healx
Intellia Therapeutics, Inc.
Editas Medicine
bluebird bio, Inc.
Sanofi
Merck & Co., Inc.
H. Lundbeck A/S
Cellectis SA
Bio-Techne
GlaxoSmithKline plc
Allergan
“*” marked represents similar segmentation in other categories in the respective section.